Amersham Health As

Nycomed Imaging As

Exxon Chemical Patents, Inc.

Seno Medical Instruments, Inc.

Paul Mark Henrichs

Robert A Snow

Edward R Bacon

Vinay Chandrakant Desai

Kenneth Robert Hollister

Jo Klaveness

John L Toner

Gregory L McIntire

Edvin Wilhelm Johannesen

Wolfgang Hans Heinrich Gunther

William Anthony Sanderson

Eric Paul Hohenschuh

Pal Rongved

Alexander A Oraevsky

David L Ladd

Henry Raphael Wolfe

Andrew J Peacock

Pål Rongved

Daniel J Delecki

Richard R Eckman

Steven Blair Coffey

Bjorn Fuglass

Bjorn Fuglaas

Edvin Wilheim Johannesen

Wolfgang Hans Heinrich

Marten Eriksen

Pangal Rongved

Gregory Lynn McIntire

Jan Alan Alfheim

Xin Peng

Dong Wei

Kenneth Edmund Keller

A method of enhancing detection for a specific object in a body. A nanoparticulate is administered to the body for location in an area to be explored for detection of the object, if present. The nanoparticulate is at least partially metallic, has a formed non-spherical shape having a minimal characteristic dimension in the range from about 1 to about 3000 nanometers, and has a formed composition capable of producing thermal pressure either in the nanoparticulate or in the object greater than the object could produce in the absence of the nanoparticulate. Electromagnetic radiation is directed into the body. The electromagnetic radiation has a specific wavelength or spectrum of wavelengths in the range from 300 nm to 300 mm selected so that the wavelength or wavelength spectrum is longer by a factor of at least 3 than the minimum characteristic dimension of the nanoparticulate. The nanoparticulate absorbs the electromagnetic radiation more than would one or more non-aggregated spherically shaped particles of the same total volume with a composition identical to the nanoparticulate. The nanoparticulate produces an enhanced optoacoustic signal resulting from the absorption that is received and converted into an electronic signal and presented for assessment of the at least one parameter by a human or a machine.

High contrast optoacoustic imaging using nanoparticles

The present invention relates to the use of particulate materials as contrast agents in in vivo light imaging.

Light imaging contrast agents

The invention relates to a method of generating an image of an animate human or non-human animal body or part thereof. The method comprises administering to said body a physiologically tolerable contrast agent comprising a radiation absorbing component and/or a pressure inducing component, exposing said body to radiation, detecting pressure waves generated in said body by said radiation and generating an optoacoustic image therefrom of at least a part of said body containing the administered contrast agent.

Methods of photoacoustic imaging

A method of treatment of a human or animal body by sonodynamic therapy in which a sensitizer agent is administered to the body and the body is exposed to ultrasound to achieve a cytopathogenic effect at a site therein, wherein the said sensitizer agent is a physiologically tolerable substance which is capable of enhancing the cytopathogenic efficacy of said sonodynamic therapy. Preferably, the sensitizer agent is a water-soluble polymer compound or a conjugate thereof.

Sonodynamic therapy using an ultrasound sensitizer compound

The invention relates inter alia to a method of generating information from an animate human or non-human animal body which method comprises: administering to said body a physiologically tolerable material capable of absorbing, scattering or emitting light at a wavelength in the range 300 to 1300 nm; subjecting at least a portion of said body to ultrasound irradiation; detecting light in the wavelength range 300 to 1300 nm from said portion of said body; and manipulating the detected light to generate said information.

Use of acousto-optical and sonoluminescene contrast agents

This invention provides a physiologically tolerable light imaging contrast agent compound having a molecular weight in the range 500 to 5000000 and containing at least two chromophores having delocalized electron systems as well as at least one polyalkylene oxide (PAO) moiety having a molecular weight in the range 60 to 100000.

Compounds

The present invention relates to the use of particulate materials as contrast agents in vivo light imaging.

The invention provides polymeric polychelants containing polymer repeat units of formula �L--Ch--L--B! (where Ch is a polydentate chelant moiety; L is an amide or ester linkage; B is a hydrophobic group providing a carbon chain of at least 4 carbon atoms between the L linkages it interconnects) or a salt or chelate thereof, with the proviso that where Ch is 2,5-biscarboxymethyl-2,5-diazahex-1,6-diyl, the polychelant is metallated with lanthanide or manganese ions or B provides a carbon chain of at least 10 carbon atoms between the L linkages it interconnects and their salts and chelates. The paramagnetic polychelates of the polychelants of the invention have remarkably high R.sub.1 relaxivities.

Polymeric contrast agents for medical imaging

This invention relates to syndiotactic polypropylene having greater than 55% racemic dyads having elastic characteristics at room or ambient temperature, a method for producing said syndiotactic polypropylene and articles made therefrom.

Syndiotactic polypropylene, methods for producing amorphous syndiotactic

Growing community of inventors

Houston, TX, United States of America

Paul Mark Henrichs